AGP
VRDN icon

Artia Global Partners’s Viridian Therapeutics VRDN Stock Holding History

Artia Global Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-160,000
Closed -$2.16M – 47
2025
Q1 		$2.16M Buy
160,000
+60,000
+60% +$1.02M 0.55% 23
2024
Q4 		$1.92M Buy
+100,000
New +$2.17M 0.69% 25

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Artia Global Partners's VRDN Position: Q2 2025 in Review

Artia Global Partners sold out of Viridian Therapeutics (VRDN) in Q2 2025, closing a stake of 160,000 shares — an estimated $2.16M sold.

Artia Global Partners first reported a position in VRDN in Q4 2024 and held it in 2 quarters. The position peaked at $2.16M in Q1 2025. 170 funds tracked by Wall St. Rank hold VRDN as of Q2 2025.

  • Artia Global Partners reported no remaining Viridian Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Artia Global Partners sold 160,000 Viridian Therapeutics shares in Q2 2025, an estimated $2.16M.
  • Artia Global Partners first reported a position in Viridian Therapeutics in Q4 2024 and held it in 2 quarters.
  • Artia Global Partners's Viridian Therapeutics position peaked at $2.16M in Q1 2025.
  • 170 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2025.

Based on Artia Global Partners's 13F filing for Q2 2025, filed 14 Aug 2025.